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BACKGROUND
The most prevalent phenotype of asthma is characterized by eosinophil-dominated 
inflammation that is driven by a type 2 helper T cell (Th2). Therapeutic targeting 
of GATA3, an important transcription factor of the Th2 pathway, may be beneficial. 
We evaluated the safety and efficacy of SB010, a novel DNA enzyme (DNAzyme) that 
is able to cleave and inactivate GATA3 messenger RNA (mRNA).
METHODS
We conducted a randomized, double-blind, placebo-controlled, multicenter clinical 
trial of SB010 involving patients who had allergic asthma with sputum eosinophilia 
and who also had biphasic early and late asthmatic responses after laboratory-based 
allergen provocation. A total of 40 patients could be evaluated; 21 were assigned to 
receive 10 mg of SB010, and 19 were assigned to receive placebo, with each study 
drug administered by means of inhalation once daily for 28 days. An allergen chal-
lenge was performed before and after the 28-day period. The primary end point was 
the late asthmatic response as quantified by the change in the area under the curve 
(AUC) for forced expiratory volume in 1 second (FEV1).
RESULTS
After 28 days, SB010 attenuated the mean late asthmatic response by 34%, as com-
pared with the baseline response, according to the AUC for FEV1, whereas placebo 
was associated with a 1% increase in the AUC for FEV1 (P = 0.02). The early asthmatic 
response with SB010 was attenuated by 11% as measured by the AUC for FEV1, 
whereas the early response with placebo was increased by 10% (P = 0.03). Inhibition 
of the late asthmatic response by SB010 was associated with attenuation of allergen-
induced sputum eosinophilia and with lower levels of tryptase in sputum and lower 
plasma levels of interleukin-5. Allergen-induced levels of fractional exhaled nitric 
oxide and airway hyperresponsiveness to methacholine were not affected by either 
SB010 or placebo.
CONCLUSIONS
Treatment with SB010 significantly attenuated both late and early asthmatic responses 
after allergen provocation in patients with allergic asthma. Biomarker analysis showed 
an attenuation of Th2-regulated inflammatory responses. (Funded by Sterna Biologi-
cals and the German Federal Ministry of Education and Research; ClinicalTrials.gov 
number, NCT01743768.)
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A sthma is a common chronic in-flammatory disease of the airways that is characterized by variable airway obstruc-
tion, hypersecretion of mucus, airway inflamma-
tion, and hyperresponsiveness of the airways. The 
dysregulation of innate and adaptive immune 
responses is considered to play a central role in 
the development of the disease. The high degree 
of interindividual heterogeneity identified in dif-
ferent patient populations has led to the definition 
of several clinical phenotypes and pathophysiolog-
ical endotypes.1 The allergic response driven by the 
type 2 helper T cell (Th2),2,3 also termed the Th2 
molecular endotype, is thought to be character-
istic of allergic asthma.4,5
Approximately half the patients with asthma, 
regardless of the severity of the disease, exhibit 
this Th2 endotype. The endotype is characterized 
by a predominant activation of Th2 cells that pro-
duce cytokines such as interleukins 4, 5, and 13. 
The expression and production of all these Th2 
cytokines have been shown in isolated cell systems 
and invertebrates to be controlled by the zinc fin-
ger transcription factor GATA3, which is essential 
for Th2-cell differentiation and activation and is 
considered to be the master transcription factor 
of the Th2 pathway of immune activation.6 The 
overexpression of GATA3 has been observed in 
specimens from bronchoalveolar lavage and lung 
biopsies obtained from patients with severe asth-
ma, even when they are receiving intensive thera-
py.7 Thus, interventions that can disrupt this im-
mune network — including treatments targeting 
components downstream of the transcription fac-
tor GATA3 — are being developed for the treat-
ment of asthma.8
Since GATA3 is expressed only in intracellu-
lar processes, we developed a GATA3-specific DNA 
enzyme (DNAzyme) with in vivo cell-penetrating 
capabilities. DNAzymes are catalytically active, 
single-stranded, synthetic DNA antisense mole-
cules that do not occur in nature. The DNAzyme 
hgd40 — the active drug product in SB010 — 
consists of 34 bases. Nine bases each at the 3′ and 
5′ region form two binding domains that are 
highly specific for binding the target messenger 
RNA (mRNA) of GATA3. The central core of the 
molecule represents the catalytic domain that ac-
counts for the cleavage of the target after the bind-
ing of hgd40 to GATA3 mRNA9,10 (Fig. S1 and S2 
in the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The hgd40 
enzyme has shown efficacy in preclinical mod-
els of allergic airway inflammation and has sig-
nificantly reduced levels of both GATA3 mRNA 
and protein and, subsequently, the production of 
Th2 cytokines in human T cells and tissue ex-
plants11,12 (Fig. S3 in the Supplementary Appen-
dix). Since unwanted, off-target effects have not 
been noted13,14 and since no major safety con-
cerns were identified in three recently completed 
randomized, placebo-controlled, dose-escalation 
phase 1 trials,15 we conducted this phase 2a trial 
to assess the efficacy of SB010.
Me thods
Study Design and Oversight
We conducted this randomized, double-blind, pla-
cebo-controlled trial between January 2013 (first 
patient enrolled) and October 2013 (last visit by 
last patient) at seven sites in Germany that spe-
cialize in respiratory research. After patient screen-
ing and baseline assessments were performed, 
participants were assigned to receive active treat-
ment or placebo for 4 weeks. Randomization was 
performed at Inamed with the use of a centrally 
generated list and with no stratification. Details 
of the study design are shown in Figure 1 and 
the protocol (available with the statistical analy-
sis plan at NEJM.org). The trial was approved by 
the German regulatory agency Bundesinstitut für 
Arzneimittel und Medizinprodukte, by a central 
ethics committee, and by the local ethics commit-
tee at each participating site and was conducted 
according to the principles of the Declaration of 
Helsinki and the International Conference on Har-
monisation Good Clinical Practice guidelines. All 
participants provided written informed consent 
before any study-specific procedures were per-
formed. Data were collected at each study site and 
entered into a database at Inamed. The statistical 
analysis was performed independently by FGK 
Clinical Research. The first draft of the manuscript 
was prepared by the first and last authors. A pro-
fessional medical writer funded by Sterna Bio-
logicals provided writing and editorial support. 
The first and last authors and the authors em-
ployed by the sponsor vouch for the accuracy and 
completeness of the data, the statistical analysis, 
and the fidelity of the trial to the final protocol.
Patients
We recruited white male patients between 18 and 
64 years of age who had received a diagnosis of 
mild asthma, according to criteria in the guide-
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lines from the Global Initiative for Asthma,16 at 
least 6 months before screening and who had 
not received treatment with any asthma medica-
tion other than inhaled short-acting bronchodi-
lators. If a patient had been receiving treatment 
with inhaled glucocorticoids, the medications were 
stopped at least 2 weeks before the screening 
visit. At the screening visit, the forced expiratory 
volume in 1 second (FEV1) had to be 70% or more 
of the predicted normal value for at least 6 hours 
after any use of a short-acting bronchodilator. The 
allergic nature of the asthma had to be confirmed 
by means of a positive response to common aero-
allergens on a skin-prick test and an allergen-
induced decline in FEV1 of 20% or more in the 
early asthmatic response and 15% or more in the 
late asthmatic response. The presence of sputum 
eosinophils (at least 1 in 400 counted cells) had 
to be confirmed either before or after the allergen 
challenge conducted at screening. The full details 
of the criteria for study inclusion and exclusion are 
provided in the protocol.
Treatment
The active product in SB010 is the GATA3-specific 
DNAzyme hgd40 (BioSpring); sequencing details 
for hgd40 are shown in Figure S4 in the Supple-
mentary Appendix. The final drug product and the 
placebo were prepared at one site in identical 
packaging by BAG Health Care. Patients received 
10 mg of SB010 in 2 ml of phosphate-buffered 
saline or matching placebo once daily for 28 con-
secutive days; both study drugs were adminis-
tered in the morning by means of flow- and vol-
ume-controlled inhalation for a duration of 3 to 
8 minutes with the use of an Akita2 Apixneb nebu-
lizer (Activaero).17 Patients administered the active 
treatment or placebo at a study site under the 
supervision of the study staff on days 1, 7, 13, 
Figure 1. Study Design and Screening and  
Randomization.
Panel A shows an overview of the study design and 
procedures. Panel B summarizes screening and ran-
domization. In the SB010 group, 21 patients complet-
ed all the study assessments; 1 patient was not eligi-
ble for evaluation because the dose of allergen 
administered in the pretreatment allergen challenge 
(AC) differed from that administered in the post-treat-
ment AC. In the placebo group, 19 patients completed 
all the study assessments; 2 patients were not eligible 
for evaluation (1 patient required treatment with a 
short-acting beta-agonist during the AC, and 1 patient 
was administered a dose in the pretreatment AC that 
differed from the dose administered in the post-treat-
ment AC). In the placebo group, the data for late asth-
matic response (LAR) were missing for 1 patient be-
cause serial spirometry was unintentionally stopped 4 
hours after allergen provocation. FeNO denotes the 
fraction of nitric oxide in exhaled air, FEV1 forced expi-
ratory volume in 1 second, IS induced sputum, MCh 
methacholine challenge, and R randomization.
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20, 26, and 28. On the remaining days, the prod-
uct was self-administered by the study patients, 
who had been trained to inhale from the device 
(with a placebo inhalant) at the screening visit.
Procedures
After a safe starting concentration had been iden-
tified,18 increasing concentrations of inhaled aero-
allergen were administered at the screening visit 
to determine the inhaled-aeroallergen regimen 
that would be used during the treatment phase.19 
Inhaled-allergen challenges were administered in 
the identical manner before randomization (pre-
treatment) and after the 28-day study period (post-
treatment).20 Serial spirometric measurements were 
performed repeatedly in accordance with recent 
guidelines.21 Appropriate washout times between 
challenges were implemented. An overview of the 
main study procedures and the interventions is 
shown in Figure 1A (a full summary of study pro-
cedures can be found in the study protocol).
Assessments
A methacholine challenge was used to assess air-
way responsiveness at the times indicated in Fig-
ure 1A. Responsiveness was determined on the 
basis of the provocative concentration of metha-
choline required to reduce the FEV1 by at least 
20% (methacholine PC20). The challenges were 
conducted in accordance with the guidelines of 
the American Thoracic Society (ATS).22 Levels of 
fractional exhaled nitric oxide (FeNO) were mea-
sured at the times indicated in Figure 1A with 
the use of a hand-held device (NIOX MINO, 
Aerocrine) in accordance with the recommenda-
tions of the ATS and the European Respiratory 
Society23 and the manufacturer’s instructions. 
Induced sputum samples were obtained at five 
time points (Fig. 1A): at screening, up to 2 weeks 
before the pretreatment challenge, 24 hours af-
ter the pretreatment challenge, 24 to 48 hours 
before the post-treatment challenge, and 24 hours 
after the post-treatment challenge. Assessment 
of cell distribution and analysis of mediators in 
the supernatant were performed at a central labo-
ratory.24 Cytokines and chemokines were mea-
sured with a type 1 helper T-cell (Th1) and Th2 
assay and a chemokine multiplex assay. The trypt-
ase level in sputum supernatants was measured 
with the use of an enzyme-linked immunosorbent 
assay.
Adverse events and any medications prescribed 
in relation to such an event were assessed at 
every visit with the use of open questions. Labora-
tory analyses (e.g., measurement of hematologic 
and clinical chemistry values and urinalysis) were 
performed before the first administration of 
SB010 or placebo and at 2-week intervals during 
the study period.
Outcome Measures
The primary outcome measure was the area un-
der the curve (AUC) for FEV1, expressed as a per-
centage of the baseline FEV1 during late asthmatic 
response (4 to 7 hours after allergen challenge), 
after administration of multiple doses of inhaled 
SB010. Secondary outcomes were the safety and 
side-effect profile of SB010, as assessed by evalu-
ation of adverse events, vital signs, electrocardio-
graphic findings, laboratory analyses, and tests 
of pulmonary function. Exploratory end points 
included the AUC for FEV1 during early asthmatic 
response (0 to 3 hours after allergen challenge), 
allergen-induced changes in airway responsive-
ness (methacholine PC20), and changes in FeNO 
and in biomarker levels in plasma and sputum 
after treatment with SB010.
Statistical Analysis
We calculated that for the study to have at least 
80% power to detect a between-group difference 
in effect size of 8% for the change in the AUC dur-
ing the late-phase asthmatic response (percent 
change in FEV1 × no. of hours), a sample of at least 
38 participants who could be evaluated would be 
required, assuming a probability of type I error 
of 10%. On the basis of an anticipated dropout 
rate of 15%, 43 patients were randomly assigned 
to receive SB010 or placebo. Efficacy and pharma-
codynamic outcomes were analyzed for all patients 
who could be evaluated (intention-to-treat popu-
lation), as indicated in Figure 1.
The primary efficacy outcome (AUC for late 
asthmatic response) was compared between treat-
ment groups with the use of an analysis-of-cova-
riance (ANCOVA) model, with the baseline AUC 
in the late asthmatic response used as the co-
variate. The calculation of the AUC was based on 
the percentage of baseline FEV1 over time with 
the use of the trapezoidal rule, as detailed in the 
statistical analysis plan in the protocol. Four 
patients in the SB010 group and three patients 
in the placebo group had a late asthmatic response 
only in the first pretreatment allergen challenge. 
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For these patients, data on lung function from this 
challenge were used as the pretreatment value; for 
all other patients, the baseline value was the re-
sponse to the second allergen challenge performed 
immediately before treatment. Other end points 
were also analyzed with the use of the same 
Figure 2. Lung Function after Allergen Challenge.
Panels A shows the forced expiratory volume in 1 second (FEV1) as a percentage of the baseline FEV1 after allergen 
challenges performed before initiation of the study drug (pretreatment), and Panel B shows these values after com-
pletion of the 28-day study period (post-treatment). After an allergen challenge, lung function was recorded for 7 
hours. Mean (±SE) values are shown. Both the early asthmatic response (EAR) and the late asthmatic response 
(LAR) were significantly attenuated after treatment with SB010 (solid line) as compared with placebo (dashed line). 
ANCOVA denotes analysis of covariance. Panel C shows the individual patient values for changes from pretreatment 
to post-treatment in the area under the curve (AUC) for the late allergic response. Panel D shows individual patient 
values for the changes in the maximum decline in FEV1 during the late allergic response. The thick black lines repre-
sent the mean values. Negative values reflect improvement and positive values reflect worsening after 4 weeks of 
receipt of the study drug. Each symbol represents an individual patient in the SB010 or placebo group. The com-
plete data set for each patient is shown in Tables S5A and S5B in the Supplementary Appendix.
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model or with Wilcoxon rank-sum tests. Safety 
outcome measures were listed according to patient, 
and descriptive statistics were calculated. Further 
details on the statistical methods are provided in 
the protocol.
R esult s
Patients
In the SB010 group, 21 patients completed all the 
study assessments; in the placebo group, 18 com-
pleted the assessment of late asthmatic response 
and 19 completed the assessment of early asth-
matic response (Fig. 1B). The demographic and 
baseline data for these patients are shown in 
Table S2 in the Supplementary Appendix.
Late- and Early-Phase Responses
As shown in Figure 2 (and Tables S3 and S4 in the 
Supplementary Appendix), the late asthmatic re-
sponse was attenuated after treatment with SB010, 
and there was a significant improvement (i.e., de-
crease) in the mean AUC from the pretreatment 
to the post-treatment allergen challenge, from 66.4 
to 44.0 (percent FEV1 × hours × 100), reflecting a 
decrease of 33.7% (as compared with a worsen-
ing [i.e., increase] of 1.4% in the placebo group) 
(P = 0.02), and an improvement (i.e., decrease) in 
the maximum decline in FEV1 from 30.1% to 
20.6%, reflecting a decrease of 31.6% (P = 0.09). 
The early asthmatic response was also attenuated, 
with a significant improvement in the mean AUC 
from 37.9 to 33.6, reflecting a mean improvement 
in the AUC of 11.3% (as compared with a wors-
ening of 10.5% in the placebo group) (P = 0.03), 
and an improvement in the maximum decline in 
FEV1 from 30.3% to 23.8%, reflecting a decrease 
of 21.5% (P = 0.04) (Fig. 2, and Tables S3 and S4 
in the Supplementary Appendix). Data for indi-
vidual patients are listed in the Tables S5A and 
S5B in the Supplementary Appendix
Interference with Markers of Th2-Driven 
Inflammation
After 28 days of treatment, SB010 attenuated the 
allergen-induced increase in sputum eosinophilia 
as compared with placebo, although this differ-
ence was not significant (P = 0.06) There was, 
however, a significant change in levels of blood 
interleukin-5 (P = 0.05) (Fig. 3). The post-treat-
ment increase in interleukin-5 levels observed in 
the placebo group was not observed in the group 
receiving SB010. At the end of the 28-day study 
period, sputum tryptase levels were significantly 
lower in the SB010 group than in the placebo 
group (median, 6.39 ng per milliliter [interquar-
tile range, 2.03 to 13.88] vs. median, 13.10 ng 
per milliliter [interquartile range, 6.05 to 22.77]; 
P = 0.05). Allergen-induced levels of FeNO and air-
way hyperresponsiveness to methacholine re-
mained unaffected by either SB010 or placebo 
24 hours after the challenge (Table S8 in the 
Supplementary Appendix).
Safety and Adverse Events
No noteworthy differences in adverse events were 
observed between patients receiving SB010 and 
those receiving placebo during the 28-day study 
period. Eight patients in the placebo group, as 
compared with six patients in the SB010 group, 
had an adverse event (Table 1). There were no 
serious adverse events during the study period. 
Figure 3. Changes from Baseline in Plasma Levels of 
Interleukin-5 after an Allergen Challenge.
Shown are the changes in plasma levels of interleu-
kin-5 after an allergen challenge between the time of 
initiation of the study drug and the completion of the 
28-day study period among patients who had detect-
able plasma levels of interleukin-5 at either time point 
or at both time points. Symbols represent the same in-
dividual patients in the SB010 and placebo groups as 
shown in Figure 2. The thick black lines represent the 
mean values. The P value is for the between-group dif-
ference in the change in values.
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The analysis of safety end points did not reveal any 
safety concerns. There were no significant be-
tween-group differences in pretreatment and post-
treatment levels of TNF-α, interleukins 1β and 8, 
monocyte chemotactic proteins 1 and 4, macro-
phage inflammatory protein 1β, macrophage-
derived chemokine, and interferon-inducible pro-
tein 10 (Table S7 in the Supplementary Appendix). 
No significant increases in levels of rheumatoid 
factor or antinuclear antibodies were detected in 
either group.
Discussion
The inhaled bronchial allergen challenge is a 
widely accepted in vivo model for the observation 
of allergic inflammation and bronchoconstric-
tion.19,25 All new therapeutic approaches targeting 
pathways of Th2 cytokines, such as interleu-
kin-4,26-28 interleukin-5,29-31 interleukin-13,32,33 and 
thymic stromal lymphopoietin (TSLP),34 which are 
now in later stages of development, were suc-
cessful in attenuating the late asthmatic response 
in early clinical trials. In this study, treatment with 
SB010 significantly improved lung function dur-
ing both early and late asthmatic responses after 
allergen inhalation. Since SB010 specifically and 
selectively targets the transcription factor GATA3, 
these data strongly support the importance of 
GATA3-dependent and regulated pathways in the 
asthmatic response after allergen inhalation in 
patients with a phenotype for Th2-driven asthma.6
The patients in our study had mild allergic 
asthma with a typical Th2-driven endotype, as 
indicated by elevated levels of eosinophils in 
blood and sputum and elevated levels of FeNO.
35,36 
This type-2 endotype not only is present in pro-
totypical atopic and allergic asthma but also has 
recently been observed in other clinical phenotypes 
of asthma, including hypereosinophilic late-onset 
asthma, persistent and severe asthma, and aspi-
rin-sensitive asthma.5,37,38 The criteria for inclusion 
in the study were designed to cover a broad spec-
trum of patients with this endotype (e.g., requir-
ing only the “presence of sputum eosinophils”), 
and the data on lung function showed that 
SB010 had a significant effect in this population. 
SB010 had a more pronounced attenuating effect 
on the late asthmatic response, but there was also 
significant attenuation in the early asthmatic re-
sponse. This dual mode of action across both 
phases of the asthmatic response has been re-
ported for anti-IgE39 and anti-TSLP34 but not in-
haled glucocorticoids.40
The central role of GATA3 in the regulation 
of the Th2 response is well established. Both the 
Organ System Specific Events SB010 (N = 22) Placebo (N = 21)
No. of  
Events
Patients  
with Event
No. of  
Events
Patients  
with Event
no. (%) no. (%)
Ear and labyrinth disorders Vertigo 1 1 (5) 0 0
Gastrointestinal disorders Diarrhea, nausea 1 1 (5) 1 1 (5)
Infections and infestations Herpes simplex, nasopharyngitis 4 3 (14) 2 2 (10)
Injury, poisoning, and procedural  
complications
Laceration 0 0 1 1 (5)
Musculoskeletal and connective-tissue  
disorders
Myalgia 1 1 (5) 0 0
Nervous system disorders Headache, sciatica 5 3 (14) 2 2 (10)
Respiratory, thoracic and mediastinal  
disorders
Asthma, bronchial obstruction, 
dyspnea, increased upper-air-
way secretion, oropharyngeal 
pain, upper-airway cough syn-
drome
3 3 (14) 5 4 (19)
Skin and subcutaneous tissue disorders Pruritus 1 1 (5) 0 0
Table 1. Adverse Events That Occurred during the 28-Day Study Period, According to Organ System.
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development and the maintenance of Th2-effec-
tor functions have been shown to depend strictly 
on GATA3.41 More recently, investigators have iden-
tified an essential function of GATA3 in type 2 
innate lymphoid cells.42 However, this transcrip-
tion factor also has important functions that ex-
tend well beyond its effects on the Th2-cell subset. 
GATA3 is also expressed in mast cells,41 eosino-
phils,43 and airway epithelial cells, where it con-
trols type 2 cytokine expression and effector 
mechanisms associated with the allergen-induced 
allergic response.44,45 After an allergen challenge, 
the early asthmatic response depends on mast-cell 
degranulation, whereas the late asthmatic re-
sponse is considered to be preferentially T-cell 
dependent and accompanied by a marked influx 
of eosinophils into the airways and the airway 
lumen. Mast-cell tryptase represents a reliable 
and robust marker of mast-cell activation and 
mast-cell degranulation. Our results indicate that 
SB010 directly or indirectly affects these effector 
cells of the asthmatic response after allergen in-
halation. It is likely that SB010 performs this in-
hibitory and modulatory function in a dual fash-
ion, both by modulating Th2 cells, and thus 
depriving effector cells of survival and activation 
factors, and by directly interfering with GATA3 
mRNA in eosinophils and mast-cells in the local 
inflamed tissue. Additional mechanistic studies 
are needed to further elucidate the biologic effects 
of treatment with a GATA3-specific DNAzyme. 
In our small study, one patient in the SB010 group 
had nausea and one had pruritus. Our database 
is too small to draw any conclusions about the 
long-term safety of this treatment, especially in 
regard to infectious events.
In conclusion, this proof-of-concept trial showed 
that treatment with the inhaled DNAzyme in 
SB010 significantly attenuated both the early-phase 
and late-phase asthmatic responses after allergen 
provocation. Further clinical studies are warrant-
ed to explore the question of whether these ef-
fects translate into clinical benefits in patients 
who have symptomatic, persistent asthma with 
a predominant Th2 phenotype.
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